Brokerages Anticipate AxoGen, Inc. (AXGN) to Announce -$0.08 EPS

Equities research analysts expect AxoGen, Inc. (NASDAQ:AXGN) to post earnings per share of ($0.08) for the current quarter, according to Zacks. Three analysts have issued estimates for AxoGen’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.10). AxoGen also posted earnings of ($0.08) per share in the same quarter last year. The firm is expected to issue its next quarterly earnings results on Wednesday, November 1st.

According to Zacks, analysts expect that AxoGen will report full year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.42) to ($0.29). For the next year, analysts expect that the business will post earnings of ($0.09) per share, with EPS estimates ranging from ($0.22) to $0.02. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover AxoGen.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The company had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.40 million. During the same period in the prior year, the business earned ($0.09) earnings per share. AxoGen’s quarterly revenue was up 46.2% on a year-over-year basis.

A number of equities research analysts have weighed in on AXGN shares. Wedbush reissued an “outperform” rating and set a $14.00 target price (down from $17.00) on shares of AxoGen in a report on Friday, May 19th. ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cantor Fitzgerald started coverage on shares of AxoGen in a report on Thursday, June 29th. They set an “overweight” rating and a $18.00 target price on the stock. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Leerink Swann started coverage on shares of AxoGen in a report on Monday, July 31st. They set an “outperform” rating and a $22.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. AxoGen presently has an average rating of “Buy” and a consensus target price of $15.90.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2796576/brokerages-anticipate-axogen-inc-axgn-to-announce-0-08-eps.html.

AxoGen (NASDAQ AXGN) opened at 14.70 on Thursday. AxoGen has a one year low of $7.65 and a one year high of $17.25. The company has a 50-day moving average of $15.88 and a 200 day moving average of $12.73. The firm’s market capitalization is $488.63 million.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of AxoGen by 3.2% in the first quarter. Vanguard Group Inc. now owns 1,121,824 shares of the medical equipment provider’s stock worth $11,723,000 after buying an additional 35,076 shares during the period. Russell Investments Group Ltd. increased its position in shares of AxoGen by 238.7% in the second quarter. Russell Investments Group Ltd. now owns 611,678 shares of the medical equipment provider’s stock worth $10,245,000 after buying an additional 431,057 shares during the period. Gilder Gagnon Howe & Co. LLC increased its position in shares of AxoGen by 1.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 568,124 shares of the medical equipment provider’s stock worth $9,516,000 after buying an additional 8,608 shares during the period. Summit Partners Public Asset Management LLC increased its position in shares of AxoGen by 27.4% in the first quarter. Summit Partners Public Asset Management LLC now owns 409,498 shares of the medical equipment provider’s stock worth $4,279,000 after buying an additional 88,140 shares during the period. Finally, State Street Corp increased its position in shares of AxoGen by 12.8% in the fourth quarter. State Street Corp now owns 352,735 shares of the medical equipment provider’s stock worth $3,175,000 after buying an additional 39,963 shares during the period. Hedge funds and other institutional investors own 64.58% of the company’s stock.

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.